



This measure has been approved by CMS for inclusion in the Quality Payment Program for 2018 reporting by the Pathologists Quality Registry. It has been updated based on the June 2017 Protocol update which includes updates to the Pathologic Staging Classification (pTNM) per AJCC 8th Edition. Additional revisions to this protocol have been made to support the AJCC 8th Edition elements and prognostic factors important to the treatment of the patient.

1. **CMS Measure ID/CMS QCDR ID:** CAP2
2. **Measure Title:** Cancer Protocol Elements for Carcinoma and Carcinosarcoma of the Endometrium
3. **Measure Description:** Cancer Protocol used for all eligible Carcinoma and Carcinosarcoma of the Endometrium specimens and all required data elements are included. The checklist covers the following procedure: Hysterectomy with/without salpingoophorectomy.
4. **Denominator:** All eligible carcinoma of the endometrium cases that require the use of a CAP cancer protocol (includes carcinomas, carcinosarcomas (malignant mixed Müllerian tumor) and neuroendocrine carcinomas arising in the endometrium).

The codes provided are meant as guidance; they cover the majority of cases, but others may potentially apply.

CPT[®] code – 88309 (for abdominal hysterectomy with/without bilateral salpingo-oophorectomy for neoplasia)

AND

Any of the ICD 10 codes:

- i. C54.0: malignant neoplasm of isthmus uteri
- ii. C54.1: malignant neoplasm of endometrium
- iii. C54.3: malignant neoplasm of fundus uteri
- iv. C54.8: malignant neoplasm of overlapping sites of corpus uteri
- v. C54.9: malignant neoplasm of corpus uteri, unspecified

Denominator note: Per the Protocol for the Examination of Specimens From Patients With Carcinoma and Carcinosarcoma of the Endometrium, this protocol should NOT be reported on the following tumor types: carcinoma arising in the uterine cervix, uterine sarcoma (including adenosarcoma), or lymphoma.

5. **Denominator Exclusions:** Biopsy procedures.
6. **Denominator Exceptions:**
 - Cases requiring intradepartmental or extra-departmental consultation.
 - Skin excisions with margins coded as 88305.
7. **Numerator:** All eligible cases containing all of the *required* elements found in the current CAP Carcinoma of the Endometrium protocol. Optional data (marked with a “+” in the CAP cancer protocol) is not required but may be present.
The current protocol, the required elements include:
 - Procedure
 - Histologic Type



- Histologic Grade
 - Myometrial Invasion
 - Uterine Serosa Involvement
 - Cervical Stromal Involvement
 - Other Tissue/Organ Involvement
 - Margins (required only if cervix and/or parametrium/paracervix is involved by carcinoma)
 - i. Ectocervical/Vaginal Cuff Margin
 - ii. Parametrial/Paracervical Margin
 - Lymphovascular Invasion
 - Regional Lymph Nodes details
 - Pathologic Stage Classification (pTNM, AJCC 8th Edition)
- * If an item is not applicable, an "N/A" listing is required.*

8. **Numerator Exclusions:** None

9. **Rationale:** The CAP cancer templates have been thoroughly researched and have been determined to contain all the elements that a clinician would need to appropriately treat a patient with a malignant disease. Therefore utilizing all the required elements found in a CAP template for malignant cases should be the very definition of a high quality report and serve as a measure of pathologist performance. An accurate and complete diagnosis as would be found in a high quality pathology report with the CAP cancer template is crucial to successful patient treatment and outcomes.

10. **NQF Number:** N/A

11. **eCQM Number:** N/A

12. **NQS Domain:** Effective Clinical Care

13. **Outcome or High Priority?:** No

14. **High Priority Type:** N/A

15. **Measure Type:** Process

16. **Inverse Measure:** No

17. **Proportional Measure:** Yes

18. **Continuous Variable Measure:** No

19. **Ratio Measure:** No

20. **If Continuous Variable and/or Ratio is chosen, what would be the range of the score(s)?:** N/A



-
21. **Number of performance rates to be submitted:** 1

 22. **Overall Performance Rate if more than 1 performance rate is to be submitted:** N/A

 23. **Is the Measure Risk-Adjusted?:** No

 24. **Data Source:** Laboratory Information System; CAP cancer protocols and pathology reports

 25. **Reference:** CAP cancer protocols and pathology reports. Endometrium 4.0.0.0 (June 2017) <http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution/Folders/WebContent/pdf/cp-endometrium-17protocol-4000.pdf>